Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)
Data

Cancers·High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)

DataHigh-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)

Back to the High-grade B-cell lymphoma with MYC and BCL2 rearrangements hub →19 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

19

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
T-cell/histiocyte-rich large B-cell lymphoma
Shares Indolent and aggressive lymphoma, International Prognostic Index (IPI), The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), R-CHOP (lymphoma chemoimmunotherapy) and the tags heme, lymphoma, subtype-page.
Cancer
Mediastinal grey zone lymphoma
Shares Indolent and aggressive lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), R-CHOP (lymphoma chemoimmunotherapy), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest and the tags heme, lymphoma, subtype-page.
Cancer
EBV-positive diffuse large B-cell lymphoma
Shares The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), R-CHOP (lymphoma chemoimmunotherapy), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, FDG PET and the tags heme, lymphoma, subtype-page.
Cancer
Primary large B-cell lymphoma of the testis
Shares CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it, International Prognostic Index (IPI), The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), FDG PET and the tags heme, lymphoma, subtype-page.
Cancer
Plasmablastic lymphoma
Shares The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, MYC, FDG PET and the tags heme, lymphoma, subtype-page.
Cancer
Monomorphic epitheliotropic intestinal T-cell lymphoma
Shares CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, FDG PET and the tags heme, lymphoma, subtype-page.
Cancer
ALK-negative anaplastic large cell lymphoma
Shares International Prognostic Index (IPI), The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, FDG PET and the tags heme, lymphoma, subtype-page.
Cancer
ALK-positive anaplastic large cell lymphoma
Shares International Prognostic Index (IPI), The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, FDG PET and the tags heme, lymphoma, subtype-page.

technologies

3

FDG PET Histopathology & immunohistochemistry Monoclonal antibodies

targets

2

drugs

1

ApprovedMonoclonal antibody (anti-CD20, chimeric)

Rituximab · Rituxan / MabThera (and biosimilars)

companies

5

Biogen Halozyme Therapeutics Hetero Drugs Mabion Roche / Genentech

pathways

1

terms

7

CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it Double-hit / high-grade B-cell lymphoma Indolent and aggressive lymphoma International Prognostic Index (IPI)R-CHOP (lymphoma chemoimmunotherapy)The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC)

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-29. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Wikipedia

Diffuse large B-cell lymphoma

Sources & links

WHO Classification of Haematolymphoid Tumours, 5th edition: lymphoid neoplasms (Alaggio, Leukemia 2022)
International Consensus Classification of Mature Lymphoid Neoplasms (Campo, Blood 2022)
Double-hit gene expression signature defines a distinct subgroup of germinal centre B-cell-like diffuse large B-cell lymphoma (Ennishi and Rosenwald, J Clin Oncol 2019)
NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional version)

heme lymphoma subtype-page

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id high-grade-b-cell-lymphoma-myc-bcl2.

WebMCP tools registered on this page: onco_search, onco_get_entity.